

September 28, 2026

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Growth Code: 4593)

**Presentation of the research results of Healios' Dual CAR-eNK cells
targeting EGFR and PD-L1 for glioblastoma
at iPSC 20th Anniversary Symposium**

HEALIOS K.K. ("Healios") announces that we will make poster presentations of our research results of Engineered human iPSC-derived Dual CAR-NK (Healios' Dual CAR-eNK*) cells targeting EGFR and PD-L1 for glioblastoma at [iPSC 20th Anniversary Symposium](#) in Kyoto, Japan from October 20 to 22, 2026.

We will present a poster for Dual CAR eNK cells. Please see below for details.

Date of presentation: Tuesday, October 20, 2026, from 18:00 to 18:45 (JST)

Venue: Kyoto International Conference Center (ICC Kyoto)

Session: Poster Session 1 (EVEN)

Poster Board No.: 118

Title: Engineered human iPSC-derived Dual CAR-NK cells targeting EGFR and PD-L1 for glioblastoma

Presenter: Yu-suke Torisawa, Yuma Fukutani, Tetsuya Sakurai, Makoto Hayashi, Norihiro Tsuneyoshi, Masashi Yamada, Kouichi Tamura, Hironobu Kimura

Presenter's Affiliation: Kobe Research institute, HEALIOS K.K. Kobe, Japan

*** CAR-eNK/ Dual CAR-eNK cells**

CAR-eNK cells are next-generation cancer immuno-cells developed from our eNK platform by introducing a chimeric antigen receptor (CAR) that recognizes molecules specifically expressed on cancer cells. CAR-eNK cells exhibit strong selectivity and powerful cytotoxic activity against target cancer cells. Thus, in addition to the innate immune activity of conventional NK cells, they possess acquired immunity-like specificity for particular cancer antigens. These features make CAR-eNK cells a promising new therapeutic approach to enhance antitumor activity against diverse cancers and overcome challenges such as therapeutic resistance. Furthermore, Dual CAR-eNK cells further enhance their ability to attack cancer cells by introducing two types of CARs.

Note: eNK cells

Development code: AKT-01/HLCN061 (engineered NK cells)

eNK cells are an iPSC-derived NK cell therapy with several functional enhancements achieved through gene-modification including enhanced recognition of and cytotoxicity towards cancer, improved persistence, increased capability to migrate to and infiltrate solid tumors, and the ability to recruit host immune cells. Healios and our development partner, Akatsuki Therapeutics, Inc., have succeeded in developing eNK cells through its own research and have confirmed the anti-tumor effect of eNK cells in mice engrafted with human lung cancer cells and human liver cancer cells. In joint research with [the National Cancer Center Japan \("the NCCJ"\)](#) Healios confirmed the antitumor effect of eNK cells in a PDX mouse disease model created using the NCCJ's JPDX samples. Healios is also conducting joint research using eNK

cells for hepatocellular carcinoma with [Hiroshima University](#) and for mesothelioma with [Hyogo Medical University](#). Akatsuki Therapeutics, Inc. and Healios are collaborating to continuing to advance eNK cells in preparation for its first clinical trials. In addition to advancing eNK cells as a monotherapy and in combination with existing drugs, Healios is developing a dual CAR-eNK cell product, in which chimeric antigen receptors (CARs) that specifically recognize cancer antigens are introduced into the eNK to facilitate enhanced targeting of certain solid cancers. Healios is studying cancer immuno-cell therapy using CAR-eNK cells against brain tumors with [Kyushu University](#).

About Healios:

HEALIOS K.K. is Japan's leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios is a pioneer in the development of regenerative medicines in Japan and owns proprietary, global platforms utilizing both somatic stem cells and iPS cells. In the somatic stem cell field, Healios is developing HLCM051(invimestrocel), a proprietary cell product comprised of multipotent adult progenitor cells ("MAPCs") derived from the bone marrow of healthy adult donors. HLCM051 has been shown to exhibit powerful anti-inflammatory and immunomodulatory properties with applicability in a range of disease states, has been tested in hundreds of patients in late stage clinical trials, is manufactured consistently at scale in 3D bioreactors, and has demonstrated both safety and suggested efficacy in hundreds of patients across multiple indications. Healios is seeking to advance HLCM051 on a global basis for ARDS, trauma, and ischemic stroke. In the iPSC regenerative medicine field, Healios has developed HLCN061, a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene-modification. These cells have demonstrated robust anti-tumor efficacy in animal models, benefit from a scalable 3D bioreactor manufacturing process. The development of AKT-01/HLCN061 is currently being led by our development partner, Akatsuki Therapeutics, Inc., in preparation for the initiation of clinical trials. Healios has also established a proprietary, gene-edited "universal donor" induced pluripotent stem cell line to develop next generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas of severe unmet medical need. Healios was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593).

<https://www.healios.co.jp/en>

Contact:
IR & PR Division
HEALIOS K.K.
E-mail: ir@healios.jp